230 related articles for article (PubMed ID: 31596961)
1. Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates.
Pineda-Moncusí M; Garcia-Giralt N; Diez-Perez A; Servitja S; Tusquets I; Prieto-Alhambra D; Nogués X
J Bone Miner Res; 2020 Feb; 35(2):291-297. PubMed ID: 31596961
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
4. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
5. Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
J Bone Miner Res; 2019 Aug; 34(8):1428-1435. PubMed ID: 31069862
[TBL] [Abstract][Full Text] [Related]
6. The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Le B; Richard L; Shariff SZ; Ouédraogo AM; Pritchard KI; Raphael J; Vandenberg T; Fernandes R; Desautels DN; Chan KKW; Earle CC
Breast; 2021 Dec; 60():295-301. PubMed ID: 34728119
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
[TBL] [Abstract][Full Text] [Related]
8. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
[TBL] [Abstract][Full Text] [Related]
9. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
10. Fracture incidence after 3 years of aromatase inhibitor therapy.
Bouvard B; Soulié P; Hoppé E; Georgin-Mege M; Royer M; Mesgouez-Nebout N; Lassalle C; Cellier P; Jadaud E; Abadie-Lacourtoisie S; Tuchais C; Vinchon-Petit S; Audran M; Chappard D; Legrand E
Ann Oncol; 2014 Apr; 25(4):843-847. PubMed ID: 24608193
[TBL] [Abstract][Full Text] [Related]
11. Practical guidance for the management of aromatase inhibitor-associated bone loss.
Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
[TBL] [Abstract][Full Text] [Related]
12. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
[TBL] [Abstract][Full Text] [Related]
13. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
14. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
17. Bone safety of aromatase inhibitors versus tamoxifen.
Lønning PE
Int J Gynecol Cancer; 2006; 16 Suppl 2():518-20. PubMed ID: 17010062
[TBL] [Abstract][Full Text] [Related]
18. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.
Hadji P
Crit Rev Oncol Hematol; 2009 Jan; 69(1):73-82. PubMed ID: 18757208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
